Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Amelia de la Rubia Nieto"'
Autor:
Belén Cabezuelo Escribano, Vicente Arocas Casañ, Beatriz Garrido-Corro, Pablo de la Cruz Murie, Mª José Blázquez Álvarez, M.ª Amelia de la Rubia Nieto
Publikováno v:
Farmacia Hospitalaria, Vol 41, Iss 3, Pp 371-381 (2017)
Objetive: To describe off-label and unlicensed drugs in clinical practice in a Neonatal Intensive Care Unit (NICU).Method: The design of the study was a descriptive and retrospective three months research in a NICU of a Spanish University Hospital. A
Autor:
Mª. Ángeles Fernández de Palencia Espinosa, Alberto Espuny Miró, Andrés Sánchez Salinas, Amelia de la Rubia Nieto, Ma Sacramento Díaz Carrasco
Publikováno v:
Journal of Oncology Pharmacy Practice. 23:443-453
Background Frequently, haematological patients undergo highly complex and intensive treatment protocols, so a high risk of drug–drug interactions could be expected. Objectives To determine prevalence of clinically relevant drug–drug interactions,
Autor:
Vicente Arocas Casañ, Jaime Mateo Carmona, Olga García Molina, Mº Ángeles Fernández de Palencia Espinosa, Mª José Blázquez Álvarez Espinosa, Mª Amelia de la Rubia Nieto, Jesús del Río García
Publikováno v:
Farmacia Hospitalaria, Vol 40, Iss 2, Pp 63-78 (2016)
Objectives: To develop a procedure for management of off-label medications, and to analyze the treatments, indications, and hospital units which will request them more frequently, as well as which variables will have an impact on the authorization de
Autor:
Sergio Vicente-Sánchez, Raquel Olmos-Jiménez, Cristina Ramírez-Roig, María José García-Sánchez, Manuel Valderrey-Pulido, Amelia de la Rubia-Nieto
Publikováno v:
Farmacia Hospitalaria, Vol 42, Iss 4, Pp 147-151 (2018)
Analyze the frequency of therapeutic noncompliance in patients who suffer early readmissions, and identify the factors associated with it.Observational, descriptive study of three months duration (March - May 2014). All patients older than 65 years w
Autor:
José Luis Alonso Romero, Alberto Espuny Miró, Ma Sacramento Díaz Carrasco, Amelia de la Rubia Nieto, Mª. Ángeles Fernández de Palencia Espinosa
Publikováno v:
International journal of clinical pharmacy. 37(6)
Background Oncological patients are at high risk for drug–drug interactions (DDIs), which may contribute to therapeutic failure or lead to serious adverse events. Objective To determine the prevalence of potential DDIs in medication lists, to descr
Autor:
Guadalupe Ruíz Merino, M. Amelia De la Rubia Nieto, Alberto Espuny Miró, M. Sacramento Díaz Carrasco, José Luis Fuster Soler, M. Angeles Fernández de Palencia Espinosa
Publikováno v:
International journal of clinical pharmacy. 36(6)
Background Onco-hematological patients are particularly susceptible to drug–drug interactions (DDIs) because they often undergo multiple combined treatments. Some studies have analyzed the frequency of DDIs in adult patients with cancer; however, t
Autor:
P De La Cruz Murie, J Mateo Carmona, J Velasco Costa, R Olmos Jimenez, C Ramirez Roig, MC Muñoz Contreras, Mª Amelia de la Rubia Nieto, M Almanchel Rivadeneyra
Publikováno v:
European Journal of Hospital Pharmacy. 21:A132.1-A132
Background This syndrome is due to a birth defect in cholesterol synthesis and caused by mutations in the DHCR7 gene, which lead to a deficiency of the enzyme that converts 7-dehydrocholesterol to cholesterol. Management is symptomatic and most patie
Publikováno v:
Nutrición Hospitalaria. 2017 Supplement2, Vol. 34, p4-101. 98p.
Publikováno v:
Nutrición Hospitalaria. may2014 supplemento 1, Vol. 29 Issue supp 1, p59-80. 22p.
Autor:
Fernández de Palencia Espinosa, Ma Ángeles, Díaz Carrasco, Ma Sacramento, de la Rubia Nieto, Amelia, Sánchez Salinas, Andrés, Miró, Alberto Espuny
Publikováno v:
Journal of Oncology Pharmacy Practice; Sep2017, Vol. 23 Issue 6, p443-453, 11p, 5 Charts